A

Aurisco Pharmaceutical Co Ltd
SSE:605116

Watchlist Manager
Aurisco Pharmaceutical Co Ltd
SSE:605116
Watchlist
Price: 21.12 CNY -4.91% Market Closed
Market Cap: 8.5B CNY
Have any thoughts about
Aurisco Pharmaceutical Co Ltd?
Write Note

Aurisco Pharmaceutical Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aurisco Pharmaceutical Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
A
Aurisco Pharmaceutical Co Ltd
SSE:605116
Total Equity
ÂĄ2B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Equity
ÂĄ25.8B
CAGR 3-Years
13%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Equity
ÂĄ13.7B
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Equity
ÂĄ42.6B
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Equity
ÂĄ39.4B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Equity
ÂĄ151.9m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurisco Pharmaceutical Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. The company is headquartered in Taizhou, Zhejiang and currently employs 1,207 full-time employees. The company went IPO on 2020-09-21. The firm's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The firm distributes its products in domestic market and to overseas markets.

Intrinsic Value
34.48 CNY
Undervaluation 39%
Intrinsic Value
Price
A

See Also

What is Aurisco Pharmaceutical Co Ltd's Total Equity?
Total Equity
2B CNY

Based on the financial report for Dec 31, 2023, Aurisco Pharmaceutical Co Ltd's Total Equity amounts to 2B CNY.

What is Aurisco Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
20%

Over the last year, the Total Equity growth was 17%. The average annual Total Equity growth rates for Aurisco Pharmaceutical Co Ltd have been 12% over the past three years , 20% over the past five years .

Back to Top